Q-omics provides the consensus-scored CASP10 profile across patient tissues and cancer cell-line models. CASP10 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CASP10 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, CASP10 protein abundance shows 19,934 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, KICH, and LSCC as cancer lineages where CASP10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CASP10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CASP10 survival associations across molecular data types. CASP10 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CASP10 RNA expression–survival associations across cancer types. High CASP10 expression shows unfavorable associations in KIRP, UVM, LIHC and LGG, but favorable associations in LUAD and SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for CASP10 RNA expression.
This table summarizes CASP10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CASP10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CASP10 shows lower tumor expression in KICH, LUSC, UCEC, COAD and BRCA and higher tumor expression in LIHC. The KICH box plot shows higher CASP10 RNA expression in normal versus tumor tissue (log2 FC = −2.095, t-test p < 0.001).
This table shows molecular features associated with CASP10 in patient tissues and cancer cell lines. In patient samples, CASP10 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CASP10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BREAST.
